Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSF standard for organic products

This article was originally published in The Rose Sheet

Executive Summary

The National Standards Foundation is accepting comments on its draft standard for organic personal-care products. The proposed standard consists of requirements for the labeling and marketing of organic personal-care products, as well as specifications for processes, production and agricultural and synthetic ingredients. The regulations cover leave-on and wash-off personal care and cosmetic products as well as oral care and personal hygiene items. To date, manufacturers seeking U.S. organic certification for their personal-care offerings have had to appeal to the USDA standards for food. Comments on the draft standards can be submitted on the NSF Web site; they will be accepted until March 3. The task force charged by NSF to develop the standards first met in early 2007 (1"The Rose Sheet" Jan. 29, 2007, p. 5)...

You may also be interested in...



Task Force To Release Standards For Organic Personal Care Products In 2007

A task force of industry reps and consumer advocates will release the first draft of standards for organic personal care products by mid-2007, insiders say

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel